Journal of cosmetic dermatology · 2025
Design, Preparation, and Ex Vivo Skin Permeation of Doxepin Microemulsion System for Topical Delivery.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kaydan Hossein Heidari, Moghimipour Eskandar, Dalvand Hossein, Jamali Nasibeh, Salimi Arghavan, Salimi Anayatollah
Аннотация
BACKGROUND: Doxepin (DX) is used orally to relieve itching but can cause side effects like blurred vision, dry mouth, and drowsiness due to its antimuscarinic effect. To reduce these adverse effects and improve skin permeation, DX is being developed in topical formulations. This study aims to improve DX skin absorption by developing a microemulsion (ME) formulation (ME-DX).
METHOD AND MATERIALS: ME formulations containing 5% DX were prepared using the phase diagram method with a mixture of essential oil (oleic acid), surfactant (Tween 80 and Labrazol), and cosurfactant (propylene glycol or PG). The physicochemical properties of these formulations were assessed to improve the topical application of DX.
RESULTS: ME droplet sizes ranged from 9.8 to 61.6 nm, with viscosities between 114 and 239 cps. Studies showed a significant correlation between DX release percentages and viscosity. ME-DX-2 released 46.51% of the drug after 24 h. Selected ME-DX formulations demonstrated Weibull, Log Wagner, and zero-order release kinetics, and improved skin permeability. ME-DX-8 exhibited an eightfold increase in Jss and P parameters compared to the control group. MEs maintained 99.9% of DX after 6 months without color changes or phase separation, indicating long-term stability.
CONCLUSION: This research demonstrates that altering the content and composition of MEs can change the physicochemical properties and permeability characteristics of DX when introduced into rats. Additionally, ME formulation shows promise as an effective vehicle for topical DX delivery in atopic dermatitis treatment.
METHOD AND MATERIALS: ME formulations containing 5% DX were prepared using the phase diagram method with a mixture of essential oil (oleic acid), surfactant (Tween 80 and Labrazol), and cosurfactant (propylene glycol or PG). The physicochemical properties of these formulations were assessed to improve the topical application of DX.
RESULTS: ME droplet sizes ranged from 9.8 to 61.6 nm, with viscosities between 114 and 239 cps. Studies showed a significant correlation between DX release percentages and viscosity. ME-DX-2 released 46.51% of the drug after 24 h. Selected ME-DX formulations demonstrated Weibull, Log Wagner, and zero-order release kinetics, and improved skin permeability. ME-DX-8 exhibited an eightfold increase in Jss and P parameters compared to the control group. MEs maintained 99.9% of DX after 6 months without color changes or phase separation, indicating long-term stability.
CONCLUSION: This research demonstrates that altering the content and composition of MEs can change the physicochemical properties and permeability characteristics of DX when introduced into rats. Additionally, ME formulation shows promise as an effective vehicle for topical DX delivery in atopic dermatitis treatment.